Rupert W. Major
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rupert W. Major has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Chee Kay Cheung
‡Infection, Immunity, and Inflammation, University of Leicester, Leicester, United Kingdom
1 shared publication- Elved Bryn Roberts
Department of Cardiology, University Hospitals of Leicester, Leicester, UK
1 shared publication - Iain B. Squire
Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
1 shared publication - Laura J. Gray
University of Leicester
1 shared publication M. Pierides
Department of Diabetes and Endocrinology, Leicester Royal Infirmary, Infirmary Square and
1 shared publication- Nigel J. Brunskill
Department of Cardiovascular Sciences, University of Leicester, and Leicester NIHR Cardiovascular Biomedical Research Unit, Leicester LE3 9QP, UK
1 shared publication
Latest Publications
- Open Access
- 1 May 2015
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 10 (5) , 732-739
Statins and Cardiovascular Primary Prevention in CKD
Background and objectives Multiple meta-analyses of lipid-lowering therapies for cardiovascular primary prevention in the general population have been performed. Other meta-analyses of lipid-lowering therapies in CKD have also been performed, but not for primary prevention. This meta-analysis assesses lipid-lowering therapies for cardiovascular primary prevention in CKD. Design, setting, participants, & measurements A systematic review and meta-analysis using a random-effects model was performed. MEDLINE was searched between January 2012 and September 2013 for new studies using predefined search criteria without language restrictions. A number of other sources including previously published meta-analyses were also reviewed. Inclusion criteria were randomized control trials of primary prevention with lipid-lowering therapy in non–end stage CKD. Results Six trials were identified, five including patients with stage 3 CKD only. These studies included 8834 participants and 32,846 person-years of follow-up. All trials were post hoc subgroup analyses of statins in the general population. Statins reduced the risk of cardiovascular disease (the prespecified primary outcome) by 41% in stages 1–3 CKD compared with placebo (pooled risk ratio, 0.59; 95% confidence interval [95% CI], 0.48 to 0.72). For the secondary outcomes, the risk ratios were 0.66 (95% CI, 0.49 to 0.88) for total mortality, 0.55 (95% CI, 0.42 to 0.72) for coronary heart disease events, and 0.56 (95% CI, 0.28 to 1.13) for stroke. In study participants with stage 3 CKD specifically, the results were similar. Conclusions This meta-analysis suggests that the use of statins in CKD for primary prevention of cardiovascular disease is effective. These findings are consistent with recent guidance for the use of statins in all patients with CKD.
- 1 May 2015
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 10 (5) , 732-739
Open AccessStatins and Cardiovascular Primary Prevention in CKD
Background and objectives Multiple meta-analyses of lipid-lowering therapies for cardiovascular primary prevention in the general population have been performed. Other meta-analyses of lipid-lowering therapies in CKD have also been performed, but not for primary prevention. This meta-analysis assesses lipid-lowering therapies for cardiovascular primary prevention in CKD. Design, setting, participants, & measurements A systematic review and meta-analysis using a random-effects model was performed. MEDLINE was searched between January 2012 and September 2013 for new studies using predefined search criteria without language restrictions. A number of other sources including previously published meta-analyses were also reviewed. Inclusion criteria were randomized control trials of primary prevention with lipid-lowering therapy in non–end stage CKD. Results Six trials were identified, five including patients with stage 3 CKD only. These studies included 8834 participants and 32,846 person-years of follow-up. All trials were post hoc subgroup analyses of statins in the general population. Statins reduced the risk of cardiovascular disease (the prespecified primary outcome) by 41% in stages 1–3 CKD compared with placebo (pooled risk ratio, 0.59; 95% confidence interval [95% CI], 0.48 to 0.72). For the secondary outcomes, the risk ratios were 0.66 (95% CI, 0.49 to 0.88) for total mortality, 0.55 (95% CI, 0.42 to 0.72) for coronary heart disease events, and 0.56 (95% CI, 0.28 to 1.13) for stroke. In study participants with stage 3 CKD specifically, the results were similar. Conclusions This meta-analysis suggests that the use of statins in CKD for primary prevention of cardiovascular disease is effective. These findings are consistent with recent guidance for the use of statins in all patients with CKD.
- Open Access
- 18 August 2014
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 108 (8) , 651-652
Bodybuilding, exogenous testosterone use and myocardial infarction
A 30-year-old male, presented with chest pain at rest. His electrocardiogram showed anteroinferior ST elevation. He underwent primary percutaneous coronary intervention (PCI) During PCI a large white thrombus was removed from the left anterior descending artery (Figure 1). There was no evidence of atherosclerotic disease. No vascular stent was deployed due to the risk of thrombus propagation.
- 18 August 2014
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 108 (8) , 651-652
Open AccessBodybuilding, exogenous testosterone use and myocardial infarction
A 30-year-old male, presented with chest pain at rest. His electrocardiogram showed anteroinferior ST elevation. He underwent primary percutaneous coronary intervention (PCI) During PCI a large white thrombus was removed from the left anterior descending artery (Figure 1). There was no evidence of atherosclerotic disease. No vascular stent was deployed due to the risk of thrombus propagation.